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PEMBANGUNAN KAEDAH MULTIPLEKS KONVENSIONAL  
PCR, REAL-TIME PCR DAN THERMOSTABIL PCR UNTUK MENGESAN 
Toxoplasma gondii 
 
ABSTRAK 
 
Toxoplasma gondii merupakan patogen yang penting dalam bidang veterinar dan 
perubatan. Parasit ini tersebar dengan meluasnya di seluruh dunia dan mempunyai 
pelbagai perumah yang merangkumi semua haiwan yang berdarah panas sebagai 
perumah perantara dan felid (kucing) sebagai perumah tetap. Jangkitan parasit ini 
biasanya tidak menunjukkan sebarang simptom di kalangan individu yang sihat tetapi 
boleh menyebabkan morbiditi dan kematian terhadap individu yang rentan daya tahan 
imun dan bayi yang dijangkiti semasa di dalam kandungan ibu. Kini kaedah biologi 
molekul semakin meluas digunakan sebagai asai pengesanan diagnostik untuk 
toksoplasmosis, terutamanya bagi spesimen cecair amnion, cecair sum-sum tulang, 
tisu plasenta, darah dan cecair mata. Walaubagaimanapun, asai PCR yang sedia ada 
untuk mengesan DNA Toxoplasma menunjukkan prestasi yang berlainan di antara 
makmal. Selain itu, penggunaan asai PCR untuk mendiagnosis Toxoplasma adalah 
masih jarang di Malaysia. Oleh itu, tujuan kajian ini adalah untuk membangunkan asai 
PCR yang pantas, spesifik dan sensitif untuk mengesan DNA T. gondii dan seterusnya 
mendiagnosis penyakit toksoplasmosis. Tiga asai PCR iaitu konvensional multipleks 
PCR, “real-time” PCR dan termostabil PCR untuk tujuan pengesanan DNA T. gondii 
telah dibangunkan. Semua “primers” dan “probes” yang digunakan dalam kajian ini 
baru direka dan kemudiannya dioptimisasikan. Kesemua asai PCR yang dibangunkan, 
xxi 
 
menunjukkan 100% spesifisiti di mana tiada sebarang timdakbalas silang dengan 
organisma yang lain di perhatikan. Bagi asai konvensional multipleks PCR, tahap 
pengesanan minimum untuk DNA dan parasit, sama ada spesimen yang tulen atau 
spiked adalah 10 pg dan 10
4
 parasit. Seterusnya, tahap pengesanan minimum bagi 
termostabil PCR adalah 100 pg dan 10
4
 parasit. Tahap sensitiviti bagi “real-time” PCR 
yang di nilai melalui kaedah “standard curve” yang di lakukan menggunakan  cecair 
badan yang ditambah (spiked) dengan parasit T. gondii mencatatkan tahap pengesanan 
sehingga 1 parasit dengan nilai R
2
 daripada 0.975 hingga 0.999. Tahap sensitiviti bagi 
asai yang dibangunkan di uji lagi dengan menggunakan pelbagai organ (otak, hati, 
limpa, hati, and ginjal) daripada haiwan yang terinfeksi. Bagi asai konvensional 
multipleks PCR, DNA parasit hanya dapat di kesan pada hati dan limpa mencit yang 
di jangkiti oleh strain RH dan tiada parasit yang dikesan pada organ mencit yang di 
jangkiti oleh strain ME49. Seterusnya, asai “real-time” PCR dapat mengesan 
kehadiran parasit dalam semua organ mencit yang dijangkiti tetapi pada tahap infeksi 
yang berbeza. Mencit yang dijangkiti dengan strain RH menunjukkan bilangan 
kehadiran parasit yang lebih tinggi bagi semua organ kecuali otak, yang mana ianya 
lebih tinggi dalam mencit yang dijangkiti oleh strain ME49. Kesimpulannya, kajian ini 
telah berjaya membangunkan tiga asai PCR bagi pengesanan DNA T. gondii. Asai 
PCR yang baru ini menawarkan ujian diagnostik molekul yang pantas, spesifik dan 
sensitif bagi pengesanan penyakit toksoplasmosis.  
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DEVELOPMENT OF CONVENTIONAL, REAL-TIME AND 
THERMOSTABILISED MULTIPLEX PCR FOR THE DETECTION OF  
Toxoplasma gondii 
 
ABSTRACT 
 
Toxoplasma gondii is an important pathogen in veterinary and human medicines. It is 
widely distributed throughout the world and has a broad range of hosts that includes 
warm-blooded animals as intermediate hosts and felid (cat) as the definitive host. 
Infection with this parasite is usually asymptomatic in healthy individuals but can 
cause morbidity and mortality in immunocompromised patients and in congenitally 
infected infants. Molecular biology is increasingly being used as a diagnostic method 
for diagnosis of toxoplasmosis, especially for specimens collected from amniotic fluid, 
cerebrospinal fluid, placenta tissue, blood and eye fluid. However, the existing PCR-
based methods for the detection of Toxoplasma DNA suffer from variations in 
performance among the laboratories. Indeed, the use of PCR-based assay for diagnosis 
of Toxoplasma is still uncommon in Malaysia. The aim of this study is to develop 
rapid, specific and sensitive PCR-based assays to detect T. gondii DNA for diagnosis 
of toxoplasmosis. Three PCR-based assays namely conventional multiplex PCR, real-
time multiplex PCR and thermostabilised PCR for the detection of T. gondii DNA 
were developed. All the primers and probes used were newly designed and optimized. 
All three PCR assays showed 100% specificity whereby no cross-reactivity with other 
organisms was observed. For conventional multiplex PCR, the detection limit for T. 
gondii DNA and whole parasite, regardless whether the T. gondii DNA and whole 
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parasite were used in pure form or spiked into specimens, were 10 pg and 10
4
 
parasites, respectively. Similarly, for thermostabilised PCR, the detection limit for T. 
gondii DNA and whole parasite were 100 pg and 10
4
 parasites, respectively. However, 
for the real-time multiplex PCR assay which was evaluated by standard curve 
constructed using human body fluids spiked with T. gondii whole parasite, the 
detection level for all types of samples was as low as 1 parasite with R
2
 value in the 
range of 0.975 to 0.999. The sensitivity of the developed assays was further evaluated 
using organs (brain, liver, spleen, heart, and kidney) of experimentally infected mice. 
For conventional multiplex PCR assay, the parasite DNA was only detected in liver 
and spleen of RH strain-infected mice and no amplification was observed in the organs 
of the ME49 strain-infected mice. On the other hand, the real-time multiplex PCR 
assay detected the presence of parasite DNA for both strains in all the organs but at 
different infection levels. The organs of the RH strain infected mice showed higher 
parasite load except for brain whereby ME49 strain infected mice showed more 
parasite load. In conclusion, the present study had successfully developed three PCR-
based assays for the detection of T. gondii DNA. These newly designed PCR-based 
assays offer rapid, specific and sensitive molecular diagnostic tests for the diagnosis of 
toxoplasmosis.
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CHAPTER ONE 
INTRODUCTION 
 
1.1  Overview of toxoplasmosis 
Toxoplasmosis is a disease caused by the protozoan parasite Toxoplasma gondii (T. 
gondii). This intracellular parasite, in the order Coccidia (Figure 1.1), is an important 
pathogen in both veterinary and human medicine. T. gondii is widely distributed 
throughout the world, and it has a broad range of hosts that includes all warm-blooded 
animals (mammal and birds) as intermediate hosts and felid (cat) as the definitive host. It 
has been estimated that as many as one-third of the human population harbors this 
zoonosis. A study from Malaysia reported a seroprevalence in Malays of 55.7% 
(Petersen, 2007). In addition, the recent calculations of the disease burden of 
toxoplasmosis rank this foodborne disease at the same level as salmonellosis or 
campylobacteriosis, according to Kijlstra and Jongert (2008). 
 
In general T. gondii can be divided into three distinct clonal lineages, type I, II and III 
(Dubey et al., 2007). The differences among these three genotypes at the genome 
sequences level is less than 1% but different types have different virulence phenotypes 
in mice (Dubey et al., 2007). The course of T. gondii infection generally benign, as the 
vast majority of the infected individual remains asymptomatic or presents only with mild 
symptoms. However, the infection can cause significant morbidity and mortality in the 
developing fetus and immunocompromised individuals. Therefore, it is very crucial to 
understand the nature of T. gondii which includes the overall aspect of  
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Scientific Classification 
Kindom Protista 
Phylum Apicomplexa 
Class Conoidasida 
Subclass Coccidiasina 
Order Eucoccidiorida 
Family Sarcosystidae 
Genus Toxoplasma 
Species T. gondii 
Binomial name Toxoplasma gondii 
 
Figure 1.1: Ultrastructure and scientific classification of a Toxoplasma gondii. The 
above figure is adapted and modified from Ajioka et al., (2001). 
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toxoplasmosis in order to provide a better prevention, diagnosis and treatment of this 
infection. 
 
1.2  Epidemiology of Toxoplasma infection 
Toxoplasmosis is a zoonosis that is widespread in human and its prevalence varies 
substantially according to countries. The prevalence of the infection rises with age and 
does not vary greatly between genders. There are considerable geographical differences 
in prevalence rate of Toxoplasma infection. Montoya and Liesenfeld (2004) recorded 
that different incidence in different climates, with lower incidence in cold regions, hot 
and arid areas, or at high elevations. For instance, the rates of positive seroprevalence 
were 18-75% in Western Europe countries, 16-93% in Central and Eastern Europe 
countries, 34-93% in Central American countries and 29.7-72% in South American 
countries. Low seroprevalence, 10.9-29.4% was reported in cold climate areas such as 
Scandinavian countries. Southeast Asia countries include Indonesia, Malaysia and 
Thailand was reported to have 2.3-58% seropositivity rates (Figure 1.2). The differences 
in the rate of incidence with the population group within the same environment may be 
explained by differences in exposure to sources of infection (Saadatnia, 2010). 
 
In the National Health and Examination Survey (NHANES) in USA from 1999-2000, 
4234 sera samples (12 to 49 years old) were collected. This survey found that 84.2% of 
childbearing age women in the United State to be seronegative, and thereby were at risk 
of acquiring T. gondii infection during gestation. On the other hand, T. gondii antibody 
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Continents Year Seropositivity (%) 
Western Europe   
Austria 1998 43 
Belgium 1997 50 
France 2001 Up to 75 
Germany 2004 26-54 
Italy 2001 18-60 
The Netherlands 2004 40.5 
Spain 2004 28.6 
Switzerland 1995 46 
UK 1992 23-33 
Scandavania   
Denmark 1999 27.8 
Finland 1995 20.3 
Norway 1998 10.9 
Sweden 2001 14.0-29.4 
Central and Eastern Europe   
Croatia 2000 38.1 
Poland 2001 46.4-58.5 
Slovenia 2002 34 
Yugoslavia 1998 57-93 
The Americas   
USA 2004 16-40 
Central America   
Costa Rica 1996 76 
Cuba 1993 60 
Mexico 2001 35 
Panama 1988 90 (at 60 years of age) 
South America   
Argentina 2001 72 
Brazil 2001 59 
West Indies 1991 29.7 
Southeast Asia   
Indonesia 2000 58* 
Malaysia 2004 44.8 
Thailand 1992, 1997, 2000, 2001                                                                2.3-21.9   
*Male: Female ratio= 63:52   
Figure 1.2: Toxoplasma seropositivity rates in Europe, the Americas and Southeast Asia 
(Petersen, 2007). 
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prevalence was higher among non-Hispanic black persons than among non-Hispanic 
white persons, and increase with age (Jones et al., 2003). Lopez et al., (2000) conducted 
an interesting study in the year 2000 and estimated that the rate of congenital 
toxoplasmosis in the United States between 1-10 per 10,000 live births and 400 to 4000 
infants would be born each year with congenital toxoplasmosis. 
 
In Malaysia the rates of toxoplasmosis seroprevalence have been reported in several 
studies. Based on the survey conducted by Nissapatorn et al., (2004) from January 2001 
to December 2002, the seroprevalence rate of toxoplasmosis among 505 HIV/AIDS 
patients that were admitted to Hospital Kuala Lumpur, was 44.8% (n=226). This 
seroprevalence rate was much higher compared with other similar studies, e.g. 15-37% 
in France (Leport & Remington, 1992), 21% in Malaysia (Nissapatorn et al., 2002), 
22.4% in Thailand (Nissapatorn et al., 2001) and 10-40% in USA (Luft & Remington, 
1988). The majority of the patients were male (75.7%), Chinese (53%), married 
(51.3%), unemployed (51.3%), heterosexual who engaged commercial sex workers 
(59.3%) and who are at risk of HIV infection (Nissapatorn et al., 2002). On the other 
hand, Azmi et al., (2003) found that the seroprevalence of toxoplasmosis in pregnant 
women in Malaysia was 49%, in which 39%, 4% and 6% were positive for anti-
Toxoplasma IgG, IgM and both IgG and IgM antibodies, respectively. In addition there 
was significant difference (p <0.05) in rates of Toxoplasma seroprevalence among three 
major races in Malaysia. The highest rate was recorded by Malays at 55.7% and closely 
followed by Indians with 55.3% and the prevalence in Chinese was 19.4% (Azmi et al., 
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2003). The highest rates in Malays can be explained by their very close association with 
cats as compared to the other two races. 
 
1.3  Discovery of Toxoplasma gondii 
The discovery of T. gondii was in 1908, by a scientist, Charles Nicolle, who was 
working in North Africa and was searching for the reservoir of Leishmania in a native 
rodent, Ctenodactylus gundi at the Pasteur Institute in Tunis (Innes, 2008). At about the 
same time, Alfonso Splendore working in Sao Paulo also discovered a similar parasite in 
rabbits. There were several other reports appeared following the discovery of the 
parasite and species of Toxoplasma were named with reference to the host species in 
which they were initially detected (Innes, 2008).  
 
The name Toxoplasma was derived from a Greek word “toxo” meaning arc or bow, 
since it resembled the crescent shaped morphology of the tachyzoite and bradyzoite 
stages of the organism while “plasma” referred to form or life (Nicolle and Manceaux, 
1909). The pathogenicity of the protozoan T. gondii to human was pointed out by three 
pathologists, Wolf, Cowen and Paige from New York, USA, who first isolated the 
organism from an infant girl who had died of congenital encephalomyelitis (Dubey, 
2009). Wolf and Cowen then outlined the classic triad of symptoms associated with 
human congenital toxoplasmosis namely hydrocephalus, retinochoroiditis and 
encephalitis (Innes, 2008). 
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1.4  Strain type  
Toxoplasma has its own ability to manipulate the immune system and establish a chronic 
infection in host. The parasite can be divided into at least three distict clonal lineages 
which are type I, type II and type III. Type I can be further characterized as RH and GT-
1 strains. Type II strain, in the other hand, as ME 49 strain and its derivatives PDS, PLK 
and PTg. Type III characterized as CEP (CTg) strain and VEG strain. These strains were 
either completely or partially sequenced (ME49, RH; Toxo DB http://www.toxodb.org ) 
and were part of T. gondii expressed sequence tag projects (ME49, RH, VEG), and/or 
have been used as the parents in genetic crosses and subsequently genotyped with more 
than 130 markers (GT-1, CEP, ME49; Toxoplasma Genome Map 
http://www.toxomap.wustl.edu ) (Saeij et al., 2005). Genetic exchanges between 
different strains can only occur in the rare event of a feline becoming infected 
simultaneously with more than one strain. According to Saeij et al., (2005), millions of 
stable and highly infectious oocysts that are secreted in the cat feces as a result of 
meiosis contain different sporozoite genotypes and huge number of genetically distinct 
organisms can be formed from a single infected cat. Animals ingesting these oocysts can 
subsequently function to select the most successful of these genotypes.   
 
1.5  Virulence and pathogenesis 
T. gondii virulence is normally defined based on LD50 (lethal dose) in mice. The T. 
gondii parasite burden is a major contributor of Toxoplasma pathogenesis in mice 
related to an over stimulation of the immune system leading to high levels of T helper 
cell type 1 (Th1) cytokines, increased apoptosis and organ damage (Weiss and Kim, 
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2007). Most of the authors focused their research on type I RH strain, followed by type 
II ME49 strain and type III VEG strain. The popularity of type I RH strain among the 
researches may be due to certain factors such as growth rate and virulence in mice. One 
tachyzoite of a type I strain is sufficient to generate high parasite loads and high levels 
of Th 1 cytokines but increased inoculation needed to obtain high parasite loads of Type 
II strain in which will result in equally high levels of cytokines and pathology. Several 
studies have noted that type I strain grow faster than type II or type III. In order to 
determine the growth factor and capability of a parasite to infect an organism, factors to 
be considered are time taken by the parasite to lyse the host cells, number of parasites in 
a culture and the doubling time. Routinely observed, the type I RH strain completely 
lyses a flask of cultured cells much faster than the type II or type III and others. The 
higher growth rate of type I parasites in cell culture have been suggested to be due to a 
higher reinvasion rather than to a shorter doubling time. Besides, the extracellular type I 
parasites remain infectious for a longer time compared with type II and type III which 
enable the parasites to disseminate more efficiently to new cells after infected cells are 
lysed. Type I strains are also found in higher number in the peritoneum than type II 
strain parasites. This ability to cross epithelial barriers rapidly and reach the blood 
stream within hours post-infection might be an important predeterminant of parasite 
dissemination in vivo in susceptible host species. Type I also has a lower rate of inter-
conversion from tachyzoite to bradyzoite than type II strains (Weiss and Kim, 2007).  
 
Although these in vitro studies demonstrated different intrinsic properties of the different 
strain, the host response is essential for expression of virulence. It is crucial to 
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understand that strain virulence is not the same across host species. As an example type I 
strains, which are highly virulent in mice, are not pathogenic in rats. Besides, congenital 
toxoplasmosis cases are predominantly associated with type I and type II strains 
(Djurkovic´-Djakovic´ et al., 2006). This shows that type II strains, which are non-
virulent in mice, can sometimes be highly pathogenic to the human fetus. 
 
1.6  Life cycle of Toxoplasma gondii 
T. gondii is a coccidian parasite that can infect a wide range of hosts and many different 
host cells (Dubey and Beattie, 1988; Dubey et al., 1998). Coccidia in general have a 
complex life cycle. Life cycle of T. gondii clearly illustrates the transmission mode and 
how it infects the body (Figure 1.3). The life cycle of T. gondii is facultatively 
heteroxenous (Frenkel and Dubey, 2000) means it has more than one obligatory host in 
its life cycle. Examples of members of Felidae are domestic or stray cats, including wild 
cat such as ocelots, margays, jaguarandi, bobcats, Pallas cats and  
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Figure 1.3: Life cycle and transmission routes of T. gondii. 
(Adapted and modified from http://www.recenttrendsofparasitology.com)  
 
 
 
 
Definitive 
host (felids)
Intermediate 
host ingests 
oocysts in fed 
of water & soil 
Accidental 
transmission
Ingests cysts in 
infected meat
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Bengal tigers. Based on the study conducted by Dr. J.K. Frenkel, of the many species of 
animals experimentally infected with T. gondii only, felids shed oocysts (Dubey, 2009). 
The study described several seroepidemiological studies that had been conducted to 
confirm the role of cat in the natural transmission of T. gondii. 
 
The results of epidemiologic studies indicated that T. gondii is transmitted most 
efficiently by carnivorism in the cat and by faecal-oral (oocysts) route in other hosts. 
During controlled studies, most uninfected cats that were fed tissues containing 
bradyzoites shed oocysts, but only less than half of the cats that were fed oocysts will 
shed oocysts (Dubey and Frenkel, 1972). In addition, the number of oocysts shed by a 
cat after ingestion of bradyzoites in infected tissues was more compared to cats that 
ingested oocysts. Thus the ingestion of infected rodents and birds by cats can lead to 
excretion of large numbers of environmentally resistant oocysts. Besides, transplacental 
infection can develop in cats, and kittens infected in utero can shed oocysts after birth 
(Dubey et al., 1993; Sato et al., 1993). However the frequency of repetitive shedding of 
oocysts in cats in the wild is unknown even though cats can shed oocysts after 
reinfection (or even without reinfection).  
 
Sexual reproduction occurs only in the feline intestinal tract. Oocyst shed by cat occur 
after ingesting of any of three infectious stages of T. gondii i.e. tachyzoites, bradyzoites 
and sporozoites (Figure 1.4 a, b, 1.5 a, b, 1.6 a, b respectively). The frequency of oocysts 
shedding varies according to the stage of T. gondii ingested. 
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Figure 1.4 a: Transmission electron micrographs of an in vitro tachyzoite within a 
parasitophorus vacuole. 
 
PV: Parasitophorus vacuole; Mi: Mitochondrion; R: Rhoptry; N: Nucleus; A: 
Apicoplast; DG: Dense granules. 
(Adapted and modified from Yahiaoui et al., 1999) 
 
 
 
1 µm 
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Figure 1.4 b: Toxoplasam gondii tachyzoites, stained with Giemsa, from a smear of 
peritoneal fluid obtained from a laboratory-inoculated mouse. 
 
(Adapted from www.dpd.cdc.gov/DPDx/html/Toxoplasmosis.com) 
 
Tachyzoites (trophozoites) of T. gondii are approximately 4-8 µm long by 2-3 µm wide, 
with a tapered anterior end, a blunt posterior end a large nucleus. They may be found in 
various sites throughout the body of the host. 
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Figure 1.5 a: Transmission electron micrographs of an in vitro bradyzoite. 
M: Micronemes; CW: Cyst wall; AG: Amylopectin granules; N: Nucleus. 
 
(Adapted and modified from Yahiaoui et al., 1999) 
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Figure 1.5 b: Tissue cyst obtained from a smear of brain homogenate from a rat 14 
months after infection with the VEG strain of T. gondii. 
 
A: Barely visible cyst wall; B: Bradyzoites. 
    (Adapted and modified from Yahiaoui et al., 1999) 
 
Cysts of T. gondii usually range in size from 5-50 µm in diameter.  Cysts are usually 
spherical in the brain but more elongated in cardiac and skeletal muscles.  They may be 
found in various sites throughout the body of the host, but are most common in the brain 
and skeletal and cardiac muscles.  
 
 
 
A 
B 
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Figure 1.6: T. gondii oocyst. (a)Transmission electron micrograph of a sporulated 
oocyst. Note the thin oocyst wall (large arrow), two sporocysts (arrowheads), and 
sporozoites, one of which is cut longitudinally (small arrows). (b) Sporulated oocyst 
with two sporocysts. Four sporozoites (arrows) are visible in one of the sporocysts.  
 
      (Adapted from Dubey et al., 1998) 
a 
b 
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The pre-patent periods after ingesting tissue cysts are 3-10 days, 18 days or longer after 
ingesting oocysts, irrespective of the dose. The pre-patent period after ingesting 
tachyzoites may vary. After ingestion of tissue cysts, the parasites invade the cat 
enterocytes, undergo several rounds of division and differentiation into 
microgametocytes and macrogametocytes. The gametocytes fuse to form zygote or 
oocysts that are shed into environment with the cat feces. The oocysts undergoes 
meiosis, producing an octet of highly infectious sporozoites that are resistant to 
environmental damage and may persist for years in warm and humid environment. 
These oocysts spread and contaminate water, soil, fruits, vegetables and animals 
(especially herbivores) following consumption of infected plant material or any of those 
mentioned above. 
 
Asexual reproduction occurs in various tissues of intermediate hosts of numerous warm-
blooded animals. It begins after the ingestion of oocysts in cat feces, contaminated 
water, or soil. The sporozoites or oocyst differentiate into rapidly dividing tachyzoites 
(also called as trophozoite). The tachyzoites will initiate the formation of tissue cysts. 
Then bradyzoites multiply slowly within the tissue cyst by a process called endodyogeny 
(Dubey, 1986; Dubey, 1993; Dubey and Beatie, 1988; Frenkel, 2000; Levine, 1961). 
These cysts are most often located within the eye, central nervous system, skeletal or 
cardiac muscles. To a lesser extent it may be present in the liver, kidney and lungs 
(Dubey, 1993; Dubey, 1998b; Dubey et al., 1998; Levine, 1961). Bradyzoites may 
persist for life in some intermediate hosts, mainly within the muscles and brain. The 
cysts are very difficult to eradicate entirely because they rest inside the host cells. 
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However, it is still unknown how the persistence mechanism occurs. Many investigators 
believed that tissue cysts breakdown periodically, with brayzoites transforming to 
tachyzoites that reinvade host cells and again transform to bradyzoites within new tissue 
cysts (Dubey, 1998; Dubey et al., 1998b; Evans, 1992; Frenkel, 2000; Remington and 
Desmonts, 1990; Weiss et al., 1998). Ingestion of bradyzoites by definitive hosts will 
initiate another asexual phase of proliferation which consist of initial multiplication by 
endodyogeny followed by repeated polygeny in epithelial cells of the small intestine. 
The terminal stages of this asexual multiplication initiate the sexual phase of the life 
cycle. 
 
1.6.1  Transmission route of Toxoplasma gondii in human 
Transmission of T. gondii in human occur via three principal routes, the first route is by 
eating raw or inadequately cooked infected meat, especially pork, mutton, and wild 
game, or uncooked foods that have come in contact with infected meat. Second, humans 
can inadvertently ingest oocysts that cats have passed in their feces, either from a litter 
box or from soil (e.g. soil from gardening, on unwashed fruits or vegetables, or 
unfiltered water). Third, women can transmit the infection tranplacentally to their 
unborn fetus. In adults, the incubation period for T. gondii infection ranges from to 10 to 
23 days after the ingestion of undercooked meat and from 5 to 20 days after the 
ingestion of oocysts from cat feces. 
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1.6.1.1  Faecal-oral route 
Epidemic of human toxoplasmosis attributed to exposure to infected cats indicate an 
important role of oocyst excretion by cats in the propagation of infection in nature and 
man (Teutsch et al., 1979). Infected cat sheds large numbers of oocysts which are 
environmentally stable and becomes a source of infection to a variety of animals and 
man. Based on a 10 year study, the risk of infection is increased when the weather is 
both warm and moist, or moderate and less moist (Afonso et al., 2006). This suggests 
that moisture increases oocysts survival during periods of heat. For maximum 
temperatures of 35
o
C, oocysts persist longer in moist than in dry areas. Prevalence 
depends on variables that influence the survival of oocysts including maximum 
temperatures, rain and location of the animals.  
 
Several outbreaks of toxoplasmosis in human beings have been linked to drinking of 
unfiltered water (Bahia-Oliveira et al., 2003; Bowie et al., 1997). Toxoplasmosis also 
may occur in developing countries that lack adequate sanitary conditions which expose 
populations to a variety of diseases. For example, an epidemic of T. gondii infection in 
Atlanta, Georgia, was attributed to dust from the floor of a horse stable that had been 
contaminated with cat feces containing oocysts. It was hypothesized that the dust was 
inhaled, then eventually swallowed, although hand to- mouth transmission or dust 
contamination of food or drinks in the stable (Petersen et al., 2000). 
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1.6.1.2  Carnivorism 
Weinman and Chandler (1954) was the first to suggest the transmission of T. gondii 
through carnivorism. Later, the idea was supported by demonstrating the T. gondii 
derived from cysts to proteolytic enzymes (Jacobs et al., 1960). They found that the 
proteolytic enzymes digested the cyst wall immediately while releasing the bradyzoites 
that were able to survive long enough to infect the host. Therefore, ingestion of viable 
cysts present in meat may result in infection, particularly among people who habitually 
eat raw or undercooked meat. Serological studies have found widespread of T. gondii 
infection in meat-producing animals, particularly pigs, sheep and goats (Aspinall et al., 
2002). Older animals, which are found to have a higher prevalence of the organism, are 
routinely used in the production of sausages, salami, and cured meats. T. gondii is killed 
when the internal temperature of meat reaches 66
o
C (Dubey, 1998) but it may survive in 
improperly grilled or barbecued meat. A study in South Kalimantan (Indonesia), 
reported that goat meat acts as a source of infection to man due to eating undercooked 
goat „sate‟ (Durfee, 1976).  
 
1.6.1.3  Congenital transmission 
A study published in 2000 reported that 30% to 63% of T. gondii infections among 
pregnant women, at various centers in Europe, could be attributed to ingestion of 
undercooked or inadequately cured meat, while 6% to 17% could be attributed to contact 
with soil (Petersen et al., 2000). Generally, congenital transmission of toxoplasmosis can 
occur transplacentally during primary infection of a pregnant woman. However, the 
mechanism of this vertical transmission is not yet well described. The probable scenario 
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for primary infected pregnant women may result in invasion of the tachyzoites into 
placenta and multiplication within cells and placenta because the mother has no 
antibodies against T. gondii during the first time infection. Then, some of these 
tachyzoites may cross the placenta and enter the fetal circulation or fetal tissue 
(Ebbesen, 2000; Remington and Desmonts, 1990). After the first infection, the antibody 
is produced and the organisms may be destroyed before it can cross the placenta, 
therefore the fetus is protected.  
 
Infection during early maternity (first and second trimester) may result in severe 
congenital toxoplasmosis which can lead to the death of the fetus in utero and 
spontaneous abortion. Conversely if infection occurs during late maternal (trimester), the 
newborns may not be infected and are born normal (Montoya and Liesenfeld, 2004). 
Infection may initially appear asymptomatic. Babies can develop chorioretinitis or 
delayed growth in the second or third decade of life if no proper treatment is applied 
(Remington et al., 2001; Wilson et al., 1980). This type of infection is also recorded in 
immunocompromised women with AIDS or receiving immunosuppressive drugs but the 
rate of vertical transmission in this setting seems to be fairly low (Minkoff et al., 1997). 
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1.6.1.4  Organ transplantation and blood transfusion 
Another route of T. gondii transmission to human is through organ transplantation. It has 
been found that organ transplantation of heart, kidney, liver and bone marrow from a 
seropositive donor to a seronegative recipient is complicated by tachyzoites or tissue 
cysts of T. gondii infections (Emelia, 2009; Duey and Beattie, 1998; Ho Yen, 1992). 
Reactivation of latent infection in the recipient is the common reason behind the 
incidence of toxoplasmosis in bone marrow, haematopoietic stem cell and liver 
transplant patients and in AIDS patients (Emelia, 2009). T. gondii can also be 
transmitted via blood or leucocytes from immunocompetent and immunocompromised 
donors (Raisanen, 1978; Siegel et al., 1971). However it has been suggested that the risk 
of transmission via blood transfusion is very low (Dubey and Beattie, 1988) because the 
parasitemia only occurs for a short period of time after the primary infection. 
 
1.6.1.5  Other routes of transmission 
Other possible ways that T. gondii parasite can make entry are through conjunctiva, 
respiratory and cutaneous routes (Beverly, 1973). Laboratory accidents also have been 
reported by contact with T. gondii contaminated needles and glassware or during 
handling of infected animals (Kayhoe et al., 1957; Remington and Gentry, 1970). 
Bonametti et al., (1997) reported a case of toxoplasmosis in a breast-fed infant whose 
mother was having acquired primary infection with T. gondii. 
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1.7  Clinical manifestations and pathogenesis of human toxoplasmosis 
Clinical manifestations and pathogenesis of toxoplasmosis in humans depends on the 
immune status of the patient or the clinical setting such as immunocompetence, 
congenital toxoplasmosis, or ocular disease. 
 
1.7.1  Immunocompetent adults and children 
Most persons infected after birth are asymptomatic established with no symptoms or an 
illness which is so mild that it is looked upon as harmless and a very temporary problem 
ascribed to a virus (Dubey and Jones, 2008). Humans are believed to remain infected for 
life and the organism reactivated only when immunosuppression occurs. It causes a self-
limited and non-specific illness which rarely needs treatment. General symptoms of 
toxoplasmosis in immunocompetent individuals are fever, lymphadenopathy, headache, 
sore throat, cough, myalgia, and dizziness. According to Tenhunen (1964), non-specific 
gastrointestinal symptoms such as nausea, vomiting and abdominal pain are prominent 
in patients with lymphadenopathy. Very infrequently, myocarditis, polymyolitis, 
pneumonitis, hepatitis or encephalitis can arise in healthy individuals (Montoya and 
Liesenfeld, 2004). 
 
1.7.2  Maternal infection and congenital toxoplasmosis 
The severity of the maternal infection depends upon the stage of pregnancy at the time 
of infection. The chances of congenital infection are 10 to 25% in untreated women who 
acquired the infection in the first trimester (Emelia, 2009). If the infection occurs during 
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the second and third trimesters, the incidence of fetal infection ranges between 30 to 
54% and 60 to 65% respectively (Lynfield and Guerina, 1997). If the infection occurs in 
early stages of pregnancy, the consequences are more severe including miscarriage 
(Remington and Desmonts, 1990), severe disease, intra-uterine growth retardation or 
premature birth. The highest frequency of severe abnormalities at birth is observed in 
children whose mothers acquired a primary infection between 10
th
 and 24
th
 week of 
gestation (Remington and Desmonts, 1990). A wide range of clinical manifestations are 
seen such as chorioretinitis which can be present for many years after birth, mental 
retardation, microcephaly, hydrocephalus and seizures. 
 
Factors related to the fetal infection are the time of maternal infection, immunological 
competence of the mother during parasitemia, parasite load and strain virulence (Tenter 
et al., 2000). Placenta as the medium transmits the parasites to the foetus almost 
immediately after maternal infection but possibly with a delay of several weeks or 
longer (Remington et al., 1995). Mildly infected children may consist of slightly 
diminished vision whereas severely infected children may have the full tetrad of signs 
including retinochorioditis, convulsions and intracerebral calcification. Among these, 
hydrocephalus is the least common but most dramatic lesion of toxoplasmosis (Dubey, 
2004). 
 
Generally, fetuses with congenital toxoplasmosis will look normal in prenatal 
ultrasound. However examples of ultrasonographic findings suggestive of congenital 
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infection are intracranial calcifications, ventricular dilation, hepatic enlargement, ascites 
and increased placental thickness (Gay-Andrieu et al., 2003). None of the signs 
described in newborns with congenital disease is pathogonomic for toxoplasmosis and 
can be mimicked by congenital infection with other pathogens such as cytomegalovirus, 
herpes simplex virus, rubella and syphilis (Montoya and Liesenfeld, 2004). 
 
1.7.3  Immunocompromised patients 
Toxoplasmosis can be life-threatening in almost all immunocompromised individuals. A 
person becomes severely immunosuppressed when the CD4+ T-lymphocyte count drops 
below 50 cells per microliter (Dubey and Jones, 2008).  In AIDS patients, the 
overwhelming majority (>95%) of toxoplasmosis cases occur as a consequence 
reactivation of latent infection (Emelia, 2009). Toxoplasmic encephalitis (TE) is the 
most common clinical manifestations in AIDS patient and in fact the most common 
cause of death among toxoplasmosis patients with AIDS (Dubey, 2004). The clinical 
presentation often includes focal encephalitis with headache, confusion, motor weakness 
and fever and if it is not treated can progress to seizures, stupor and coma. The most 
common focal neurological findings are speech abnormalities and hemiparesis (Luft et 
al., 1993). The primary lesion is cerebral necrosis, particularly of the thalamus and 
pneumonia, other disseminated systemic disease or retinochoroiditis. Clinically severe 
symptoms also can be observed in immunosuppressed patients with malignancies and 
after transfusions or transplant with immunosuppressive therapy (Dubey and Jones, 
2008). However after the introduction of primary prophylaxis against T. gondii and 
